Can analysts adopt a bullish outlook for Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS)?

February 15, 2018 - By Ellis Scott

 Can analysts adopt a bullish outlook for Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS)?

Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) Ratings Coverage

Among 5 analysts covering Sunesis Pharmaceuticals (NASDAQ:SNSS), 2 have Buy rating, 1 Sell and 2 Hold. Therefore 40% are positive. Sunesis Pharmaceuticals had 11 analyst reports since July 24, 2015 according to SRatingsIntel. TH Capital downgraded it to “Sell” rating and $1 target in Friday, July 24 report. The firm has “Hold” rating by Cantor Fitzgerald given on Thursday, July 27. The stock has “Hold” rating by Cantor Fitzgerald on Friday, July 24. The rating was initiated by Oppenheimer on Thursday, December 14 with “Buy”. Oppenheimer initiated the stock with “Buy” rating in Monday, November 20 report. The rating was downgraded by Cowen & Co to “Market Perform” on Friday, July 24. On Tuesday, July 18 the stock rating was maintained by Cantor Fitzgerald with “Hold”. The rating was upgraded by Wells Fargo on Monday, December 11 to “Buy”. The rating was upgraded by Wells Fargo on Friday, July 29 to “Outperform”. Wells Fargo downgraded the shares of SNSS in report on Tuesday, December 5 to “Market Perform” rating. Below is a list of Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) latest ratings and price target changes.

14/12/2017 Broker: Oppenheimer Rating: Buy New Target: $7.0 Initiate
11/12/2017 Broker: Wells Fargo Rating: Buy Upgrade
05/12/2017 Broker: Wells Fargo Old Rating: Outperform New Rating: Market Perform Downgrade
20/11/2017 Broker: Oppenheimer Rating: Buy New Target: $7.0 Initiate
02/11/2017 Broker: Cowen & Co Rating: Hold

The stock increased 0.33% or $0.02 during the last trading session, reaching $6.04. About 94,099 shares traded. Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) has risen 8.33% since February 15, 2017 and is uptrending. It has underperformed by 8.37% the S&P500.

Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. The company has market cap of $206.86 million. The firm is developing vosaroxin, an anticancer quinolone derivative for the treatment of acute myeloid leukemia . It currently has negative earnings. It has completed a Phase III, randomized, double-blind, and placebo-controlled trial of vosaroxin in combination with cytarabine in patients with relapsed or refractory AML.

More notable recent Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) news were published by: Seekingalpha.com which released: “Sunesis Pharmaceuticals: SNS-062 Could Be The Company’s Salvation” on August 29, 2017, also Streetinsider.com with their article: “UPDATE: Oppenheimer Starts Sunesis Pharmaceuticals Inc. (SNSS) at Outperform” published on November 21, 2017, Seekingalpha.com published: “Sunesis Pharmaceuticals: Overhang Cleared For This Oncology Turnaround Story” on October 26, 2017. More interesting news about Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) were released by: Globenewswire.com and their article: “Sunesis Pharmaceuticals Reports Third Quarter 2017 Financial Results and …” published on November 02, 2017 as well as Nasdaq.com‘s news article titled: “Sunesis Pharmaceuticals Appoints Industry Veteran H. Ward Wolff to the Board …” with publication date: February 07, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.